[Clinical study of deoxyribonucleotidum for adjuvant treatment of pulmonary tuberculosis with hepatic lesion].
To evaluate of therapeutic efficacy of deoxyribouncleotidum on pulmonary tuberculosis. Eighty patients with pulmonary tuberculosis sustaining hepatic lesion after treatment with antituberculosis drugs were randomized into therapeutic group and control group. Patients in the control group received regular treatment and those in the therapeutic group had additional deoxyribouncleotidum injection. ALT, AST, ALP and TBIL levels were significantly higher in the therapeutic group than in the control group 4 weeks after treatment. IgG, IgA, IgM levels, and CD3(+) and CD8(+) lymphocytes were significantly increased in the therapeutic group after treatment (P<0.05). deoxyribouncleotidum can improve hepatic function and immunity in patients with pulmonary tuberculosis.